Mendra
Develops and commercializes rare disease therapies using AI
$82MSeries A
Role not disclosed8
8VC
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
8VC invests in and builds technology companies in life sciences, healthcare, manufacturing, enterprise software, logistics and defence.
Its Build programme creates companies when the team identifies an opportunity without an existing business to back. This adds a company-formation route to its conventional investment activity, relevant to entrepreneurs developing a technology platform from the outset.
The firm also runs engineering and Bio-IT fellowships connecting emerging technical talent with its companies. These programmes reflect its emphasis on recruiting builders for sectors where software, scientific expertise and physical operations intersect.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $209.5M 3 disclosed · full round size, not this investor’s share